# Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

Study · id `cardio:ct-nct02476006` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02476006](<https://clinicaltrials.gov/study/NCT02476006>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02476006

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 998 participants.

## Technical summary

Registry record NCT02476006. Allocation not applicable; no masking; primary purpose treatment. Start 2015-06-23 (actual); primary completion 2019-04-12 (actual). Results posted on 2020-03-30.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 998 participants (enrolled count; ClinicalTrials.gov record NCT02476006, source copy `cardio:ctgov-nct02476006-2022-03-28`, retrieved 2026-10-31)
- Started: 2015-06-23 (actual) (ClinicalTrials.gov record NCT02476006, source copy `cardio:ctgov-nct02476006-2022-03-28`, retrieved 2026-10-31)
- Primary completion: 2019-04-12 (actual) (ClinicalTrials.gov record NCT02476006, source copy `cardio:ctgov-nct02476006-2022-03-28`, retrieved 2026-10-31)
- Completion: 2019-04-12 (actual) (ClinicalTrials.gov record NCT02476006, source copy `cardio:ctgov-nct02476006-2022-03-28`, retrieved 2026-10-31)
- Results first posted: 2020-03-30 (ClinicalTrials.gov record NCT02476006, source copy `cardio:ctgov-nct02476006-2022-03-28`, retrieved 2026-10-31)
- Countries: Austria; Belgium; Canada; Czechia; Denmark; Finland; France; Germany; Greece; Hungary; Poland; Romania; Slovakia; Slovenia; Spain; Switzerland (ClinicalTrials.gov record NCT02476006, source copy `cardio:ctgov-nct02476006-2022-03-28`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02476006-2022-03-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)
- Condition: Hypercholesterolemia
- Intervention (Drug): ALIROCUMAB SAR236553 (REGN727)
- Intervention (Drug): placebo (for injection training only)
- Intervention (Drug): ezetimibe
- Intervention (Drug): atorvastatin
- Intervention (Drug): rosuvastatin
- Intervention (Drug): simvastatin
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY
- Collaborator: Regeneron Pharmaceuticals
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Ezetimibe (`cardio:ezetimibe`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry intervention name matches this record: Simvastatin (`cardio:simvastatin`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)
- Registry lists this organization as a collaborator: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)

## Provenance

Content hash: 8d2320ee061b89a1434ac5b410748c9482d99e4536c7789fe55697dd4b2e54e9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
